A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma

@article{Witte1995API,
  title={A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma},
  author={Robert S. Witte and Traci L Leong and Marc S. Ernstoff and Robert L. Krigel and Martin M. Oken and Jules E. Harris and Douglass C. Tormey and Donald L. Trump},
  journal={Investigational New Drugs},
  year={1995},
  volume={13},
  pages={241-247}
}
Biologic response modifiers have activity in renal cell carcinoma. The combination of interleukin-2 (IL-2) and beta-interferon (B-IFN) is synergisticin vitro. This trial was initiated to determine the efficacy of IL-2 alone and with B-IFN in advanced RCC. Ambulatory patients with advanced RCC were randomly allocated to either IL-2 6×106 units/ M2 intravenously (IV) three days a week for four weeks or IL-2 5×106 units/M2 IV plus B-IFN 6×106 units/ M2 IV three days a week for 4 weeks. This… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 13 references

: the National Biotherapy Study Group experience

RA Figlin, A Belldegrun, N Moldawer, J Zeffren, J deKernion
cancer • 1993

A phase II trial of interleukin - 2 and interferon alfa - 2 a in patients with advanced renal cell carcinoma

DH IIson, RJ Motzer, +7 authors GJ Bosl
Eur J Cancer • 1993

Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 1990
View 1 Excerpt